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Various experiments have demonstrated that immune precipitates (IPs) are not solubilized by complement in the absence 
of alternative pathway function. To determine whether the characteristics of the IPs were responsible for these observa- 
tions, we studied the solubilization (Sol) of IPs formed by bovine serum albumin (BSA)-rabbit antiBSA and tetanus 
toxoid (TT)-human antiTT. Sera deficient in properdin solubilized a fraction of BSA-antiBSA precipitates, although only 
when the IPs were formed in antibody excess. The same sera solubilized TT-antiTT precipitates with some delay but 
almost as efficiently as normal serum. Factor D-depleted serum solubilized a fraction of TT-antiTT precipitates too, indi- 
cating that Sol may proceed through activation of the classical pathway only. Thus, the requirements for complement- 
mediated Sol depend on the characteristics of the IPs and do not necessarily include alternative pathway function. 
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1. INTRODUCTION 
In 1975, Miller and Nussenzweig [l] reported 
that complement solubilizes immune precipitates 
(IPs). Multiple studies have demonstrated that the 
covalent binding of C3b to antigen and antibody 
molecules was responsible for the fragmentation of 
the lattice [2-41. Solubilization (Sol) was shown to 
be dependent on both pathways of complement, 
alternative pathway activation being essential for 
Sol, and the classical pathway allowing a rapid in- 
itiation of the process, i.e. the initial C3b deposi- 
tion [ 1,5-71. Significant solubilization did not 
occur in the absence of C3, Factor B, Factor D or 
Properdin [7-l 11. However Sol differs widely 
from one type of IP to another, depending on the 
antigen/antibody ratio used to form the IP and the 
characteristics of the antigens and the antibodies 
[2,12,13]. 
For these reasons we reinvestigated the Sol of 
different types of IPs in reagents with defective or 
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absent alternative pathway function, i.e. in 
properdin-deficient sera (Pdef), and in serum that 
had been immunochemically depleted of Factor D 
(RD). 
2. MATERIALS AND METHODS 
. 
2.1. Immune precipitates 
Bovine serum albumin (BSA) (Calbiochem) was radiolabelled 
with “‘1 by the lactoperoxidase method (Calbiochem). 
Precipitating rabbit antiBSA antibodies (Dako) were depleted 
of cross-reactive anti-human serum albumin (HSA) antibodies 
by adsorption with ghttaraldehyde cross-linked HSA (Swiss Red 
Cross). After determining the equivalence point, IPs were form- 
ed at different antibody/antigen ratios from equivalence to 
lo-fold antibody excess. After centrifugation (3000 x g for 
15 min) the precipitates were suspended in phosphate buffered 
saline (PBS, Oxoid). The concentration of IPs was determined 
by the Folin method. 
Radiolabelled tetanus toxoid (TT)-human antiTT IPs were 
prepared at equivalence [ 141. 
2.2. Sol and immune assays 
The Sol assay was performed as described [ll]. Briefly, IPs 
were added to 100 pl of serum in a final volume of 200 pl using 
PBS as a diluent. The mixtures were incubated at 37°C and ali- 
quots (40 ~1) were removed at various intervals and mixed with 
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1 ml cold PBS. The percentage soluble radioactivity was deter- 
mined after centrifugation at 3000 x g for 15 min. The Sol of 
BSA-rabbit antiBSA precipitates, formed at equivalence, was 
studied using various concentrations of IPs, from 13 pg/ml to 
130 pg/ml (relative concentration of IPs to ml of serum). Sol of 
IPs at 4- and IO-fold antibody excess was performed with IP 
concentrations of 40 gg/ml and 24 Bg/ml, respectively. The 
concentration of TT-human antiTT precipitates was 10 pg/ml 
of human serum. Adherence of solubilized TT-antiTT com- 
plexes to human erythrocytes was determined using the fraction 
of soluble complexes obtained after centrifugation 1151. 
2.3. Sera and purified proteins 
Fresh normal sera were obtained from healthy donors and 
stored in liquid nitrogen. The sera of patients with properdin 
deficiency (Pdef) [16], Factor I deficiency [17], and Clq defi- 
cient serum (Clq def) (kindly provided by M. Walport) were 
stored at - 70°C before use. 
Normal serum depleted of Factor D (RD) was prepared by af- 
finity chromatography using rabbit polyclonal antiFactor D an- 
tibodies. Rabbits were immunized with purified Factor D 
(kindly provided by J. Volanakis) three times in complete 
Freund’s adjuvant at biweekly intervals. Two weeks following 
the last immunization, the serum was shown to contain an- 
tibodies against Factor D using a functional plate assay for Fac- 
tor D [IS]. The IgG fraction of this antiserum was bound to 
cyanogen bromide-activated Sepharose (Pharmacia). The an- 
tiFactor D affinity-chromatography step removed all functional 
Factor D (limit of sensitivity for the haemolytic assay: 0.1% of 
normal Factor D concentration, i.e. more than 99.9% of Factor 
D was removed). The RD was concentrated to 2/3 of its original 
volume and stored in liquid nitrogen until usage. The 
haemolytic activity of RD could be restored to normal (as com- 
pared to the initial serum) with purified D in a functional alter- 
native pathway plate assay [18]. In the Sol experiments, RD was 
compared to its initial serum. Clq def serum was depleted of 
Factor D (RD/Clq def) in the same way. Sera devoid of C3 
function were obtained by depleting C3 with cobra venom fac- 
tor [15]. Classical pathway function was blocked by adding 
10 mM ethyleneglycol tetraacetate and 2 mM magnesium 
(MgEGTA). 
Properdin was purified according to Medicus et al. (191. 
The concentration of antiTT antibodies in human sera was 
measured by a standard ELISA technique, the antihuman IgG 
being a peroxidase-conjugated rabbit IgG (Pasteur); the con- 
centrations measured were compared to that of the antiTT IgG 
(Berna) used to form the 1Ps. The RD was prepared from a 
serum that contained no antiTT antibodies. 
3. RESULTS 
When formed at equivalence, BSA-rabbit anti- 
BSA IPs were not solubilized by 4 different Pdef 
sera even after an incubation of 120 min; in nor- 
mal human serum Sol increased from 8 +- 2.5% to 
86 -+ 13% using decreasing concentrations of IPs 
(from 130 pg/ml to 13 pug/ml), whereas Sol was 
about 4% in Pdef sera at all IP concentrations. 
However, when the IPs were prepared in antibody 
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excess, significant Sol could be demonstrated in 
Pdef sera (fig.l), although the percentage of IPs 
solubilized never reached the normal range. When 
the classical pathway activation was blocked with 
MgEGTA, Pdef sera lost their capacity to 
solubilize IPs formed in antibody excess (Sol I 
4%; normal range 30 + 10% and 50 + 20% for IPs 
formed at 4- and lo-fold antibody excess, respec- 
tively). Two different Factor I deficient sera, i.e. 
depleted in C3, were unable to sustain any Sol. 
These observations, suggesting that Sol could take 
place despite the absence of properdin, led us to 
study the Sol of IPs made with human antibodies, 
i.e. TT-antiTT precipitates. 
When Sol of the two types of IPs formed at 
equivalence was compared, striking differences 
became evident (fig.2). TT-human antiTT IPs were 
solubilized in the absence of properdin, and 
although the reaction was slightly delayed, the 
percentage solubilized at 120 min was in the nor- 
mal range. Purified properdin restored the normal 
rate of Sol. Three different properdin deficient 
sera were tested, and similar results were obtained. 
Sol was not due to the presence of antiTT an- 
tibodies in the Pdef sera: the titer of antiTT an- 
tibodies was less or equal to that used to form the 
IPs, i.e. the reaction occurred in no more than 
twofold antibody excess, a concentration of an- 
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Fig.1. Solubilization of BSA-antiBSA precipitates by 4 
different Pdef sera. The percentage of soluble immune 
complexes (ICs) in the Pdef sera (closed symbols) and in the 
same sera in the presence of 10 mM EDTA (open symbols) was 
determined after an incubation of 120 min at 37°C. Sol of IPs 
formed at 4-fold and lo-fold antibody excess in normal serum: 
64 f 20%. and 90 * IO%, respectively. 
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Fig.2. Solubilization of immune precipitates formed at 
equivalence: (A) Sol of BSA-rabbit antiBSA (13 pg/ml), and 
(B) of TT-human antiTT (lOpg/ml) by NHS (O---O), by Pdef 
serum ( M), by Pdef serum repleted with P (2pg/ml) 
(a), and by Pdef serum in the presence of MgEGTA 
(+--+). In the presence of 10 mM EDTA, no Sol was observed 
in either system. 
tibodies that did not produce any dissociation of 
IPs (24 h at room temperature in PBS) and that 
did not modify Sol in normal human serum (not 
shown). 
The incorporation of C3b into immune com- 
plexes (ICs) solubilized by Pdef sera was 
demonstrated by immune adherence. The ICs 
solubilized after 30 min were exposed to human 
erythrocytes: 31% of them bound to the 
erythrocyte C3b receptors as compared to 43% of 
those solubilized by normal serum (52% binding 
to erythrocytes that have been stripped of their 
C3b receptors by trypsin treatment) [15]. 
Table 1 
Solubilization of preformed TT-antiTT immune precipitates by 
different reagents after an incubation of 120 min at 37°C 
Reagent Reagent TT-antiTT IP 
added solubilized (%) 
NHS” - 95 
NHS 10 mM EDTA 11 
RD - 40 
RD 6% Factor Db 47 
RD 30% Factor D 76 
RD 100% Factor D 89 
RD MgEGTA 12 
Clq def/RD - 11 
Clq def - 70 
C3 depleted _ 10 
Buffer - 12 
a Used to obtain RD 
b 100% of Factor D added corresponds to 2 /g/ml 
RD was able to promote Sol of TT-human an- 
tiTT IPs, although this Sol was reduced (table 1). 
Purified D increased Sol in a dose dependent man- 
ner. The addition of MgEGTA to RD abolished 
Sol, indicating that Sol was probably due to the 
classical pathway activation; this was demon- 
strated by depleting Factor D in a Clq def serum: 
the RD/Clq def reagent did not mediate any Sol. 
RD did not solubilize BSA-antiBSA IPs. 
4. DISCUSSION 
The results obtained in this work demonstrate 
that some types of immune precipitates can be 
solubilized by activation of the classical pathway 
of complement only, with no need for alternative 
pathway function. 
The Sol reaction is highly dependent on the an- 
tigen and the antibodies used to form the 
precipitates, and the antigen-antibody ratio deter- 
mines the extent of Sol as well [13]. The initial 
observation of some Sol of rabbit IPs formed in 
antibody excess in human serum deficient in pro- 
perdin, led us to question the general statement 
about the requirement for an alternative pathway 
(AP) function. Thus, we further investigated Sol 
by human serum of IPs made with human an- 
tibodies. Our results show, that the Sol of TT- 
antiTT does not require properdin. Furthermore 
complete blockade of AP function, as obtained by 
depleting Factor D, did not abolish Sol. 
The absence of total dependence on the AP 
function has already been suggested, Genin and 
Lesavre [20] depleted human serum of Factor B by 
heat inactivation at 50°C and showed that 
radiolabelled antiTT antibodies were released from 
TT-antiTT precipitates formed in antigen excess, 
but not from those formed in equivalence or an- 
tibody excess. 
The results presented here do not contradict 
previous observations. The mechanism of comple- 
ment activation responsible for Sol may be very 
different from one IP to another. In addition to 
the characteristics of the antigen and the antigen- 
antibody bonds, the Fc-Fc interactions are likely to 
participate to the structure of IPs formed in an- 
tibody excess. ‘IT-human antiTT precipitates 
formed at equivalence might also be held together, 
in part, by Fc-Fc interactions. The rapid initial 
precipitation of antigen-antibody complexes form- 
133 
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ed at equivalence has been shown to be due to Fc- 
Fc interactions [21], and this precipitation is block- 
ed by activation of the classical pathway of com- 
plement [9]. Thus, Sol by the classical pathway 
might be due to the disruption of such weak Fc-Fc 
interactions. 
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